Moderna, Inc. (NASDAQ:MRNA) Receives $43.59 Consensus Target Price from Analysts

Moderna, Inc. (NASDAQ:MRNA) has earned a consensus recommendation of “Hold” from the twenty-four ratings firms that are presently covering the firm, Marketbeat reports. Four research analysts have rated the stock with a sell recommendation, sixteen have issued a hold recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $42.8824.

Several equities analysts have recently weighed in on the company. Royal Bank Of Canada cut their price objective on Moderna from $32.00 to $28.00 and set a “sector perform” rating on the stock in a report on Friday, May 2nd. Cowen assumed coverage on Moderna in a report on Sunday, July 13th. They set a “hold” rating on the stock. Evercore ISI set a $32.00 price objective on Moderna in a report on Friday, August 1st. Bank of America cut their price objective on Moderna from $26.00 to $25.00 and set an “underperform” rating on the stock in a report on Tuesday, July 22nd. Finally, Wells Fargo & Company reiterated an “equal weight” rating on shares of Moderna in a report on Sunday, July 13th.

Hedge Funds Weigh In On Moderna

Several institutional investors have recently modified their holdings of MRNA. Raymond James Financial Inc. bought a new position in shares of Moderna during the 4th quarter valued at about $8,493,000. Townsquare Capital LLC raised its position in Moderna by 14.2% in the 4th quarter. Townsquare Capital LLC now owns 6,040 shares of the company’s stock valued at $251,000 after buying an additional 752 shares during the last quarter. Freedom Investment Management Inc. raised its position in Moderna by 50.3% in the 4th quarter. Freedom Investment Management Inc. now owns 8,071 shares of the company’s stock valued at $336,000 after buying an additional 2,701 shares during the last quarter. Forum Financial Management LP acquired a new stake in Moderna in the 4th quarter valued at approximately $225,000. Finally, First Trust Advisors LP raised its position in Moderna by 5.0% in the 4th quarter. First Trust Advisors LP now owns 668,467 shares of the company’s stock valued at $27,795,000 after buying an additional 31,645 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Trading Up 3.4%

Shares of MRNA opened at $27.12 on Wednesday. Moderna has a 1 year low of $23.15 and a 1 year high of $84.28. The stock has a market cap of $10.55 billion, a P/E ratio of -3.60 and a beta of 1.83. The stock’s 50-day moving average price is $29.18 and its two-hundred day moving average price is $29.05.

Moderna (NASDAQ:MRNA) last issued its earnings results on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.99) by $0.86. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The firm had revenue of $142.00 million for the quarter, compared to analysts’ expectations of $116.26 million. During the same quarter last year, the business earned ($3.33) earnings per share. The company’s revenue was down 41.1% compared to the same quarter last year. Moderna has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Moderna will post -9.61 EPS for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.